BIALNetworking AreaAbout BIAL
BIAL is a 100-year-old innovation-driven biopharmaceutical company dedicated to
discovering, developing, and commercializing medicines.
Being a fully integrated company strongly committed to therapeutic innovation,
BIAL has established an ambitious R&D program, consistently investing more than
20% of its annual revenue in this field. Key focus areas for the company are the
neurosciences and rare diseases.
As a result of a longstanding strategy focused on R&D, BIAL has launched and
commercialised two medicines: eslicarbazepine acetate in 2009 and opicapone in
2016.
The launch of its research drugs was crucial to boosting BIAL’s internationalisation.
In Europe, BIAL has a production site and R&D unit in Portugal (headquarters) and
affiliates in several countries - Spain, Germany, United Kingdom, Italy, and
Switzerland. Additionally, BIAL is also present in the US and emerging markets such
as Mozambique, Angola, Ivory Coast, and Panama.
The company’s internationalisation strategy also sought the establishment of
partnerships and license agreements with well-established partners namely in the
US, Japan, China, Australia, and South Korea. BIAL products are present in fifty
countries, fulfilling its purpose of making a real difference in the lives of people
living with severe diseases across the world.
